Shots:

• The P-III PREVENT-19 study involves assessing the efficacy- safety- and immunogenicity of NVX-CoV2373 with Matrix-M adjuvant vs PBO in 29-960 participants aged ≥18yrs. across 119 sites in the US and Mexico
• The study demonstrated 100% protection against mod. & sev. disease- 90.4% efficacy overall- and met the 1EPs. The study also showed 93% efficacy against circulating variants of concern and variants of interest & 91% efficacy in high-risk populations
• The company plans to file for regulatory authorizations in Q3’21- following the completion of the final phases of process qualification and assay validation needed to meet CMC requirements

  | Ref: GlobeNewswire | Image: Fierce Biotech